​
Login / Signup

Reply: Aspirin and GLP-1RAs-The missing confounders of empagliflozin for MASLD without diabetes mellitus?

Michael Ka-Shing CheungWai-Keung Leung
Published in: Hepatology (Baltimore, Md.) (2024)
Keyphrases
  • low dose
  • wild type
  • cardiovascular events
  • antiplatelet therapy
  • glycemic control
  • acute coronary syndrome
  • type diabetes
  • percutaneous coronary intervention
  • cardiovascular disease
  • adipose tissue
  • metabolic syndrome
  • atrial fibrillation